Literature DB >> 18379935

Atypical ocular presentations of Rosai-Dorfman disease.

Raju Sarwal1, Elmer Tu, Frank I Mendelblatt, Joel Sugar, Steven A Gross, Jose S Pulido, Deepak P Edward.   

Abstract

PURPOSE: To report atypical ocular findings of Rosai-Dorfman disease and to determine association with parvovirus 19.
DESIGN: The study is an observational case series of three patients that had atypical ocular presentations of Rosai-Dorfman disease.
METHODS: A multicenter, retrospective case series of 3 patients was evaluated for varied ocular complaints, including enlarging epibulbar masses and uveitis. Histologic specimens were examined retrospectively for parvovirus 19 antigen.
RESULTS: Patients presented with ocular findings prior to or concurrently with systemic findings, with and without associated lymphadenopathy. Two cases presented with epibulbar masses, one with the mass as the only sign of disease while the other exhibited multinodal involvement with bilateral epibulbar masses and anterior granulomatous inflammation. Parvovirus B19 antibody staining was negative in these cases. The final case exhibited bilateral anterior granulomatous inflammation and choroidal infiltrates.
CONCLUSIONS: Ocular findings may be the sole or presenting complaint in Rosai-Dorfman disease prior to recognition of systemic disease and should be considered in the differential diagnosis of epibulbar masses as well as anterior and posterior granulomatous inflammation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379935     DOI: 10.1080/09273940801923911

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  10 in total

1.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

Authors:  Sofia Garces; L Jeffrey Medeiros; Keyur P Patel; Shaoying Li; Sergio Pina-Oviedo; Jingyi Li; Juan C Garces; Joseph D Khoury; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

2.  Rosai-Dorfman disease simulating nodular scleritis and panuveitis.

Authors:  John F Payne; Sunil K Srivastava; Jill R Wells; Hans E Grossniklaus
Journal:  Arch Ophthalmol       Date:  2011-04

3.  Ophthalmic Manifestations of Rosai-Dorfman Disease in Five Patients.

Authors:  Babak Masoomian; Sara E Lally; Jerry A Shields; Carol L Shields
Journal:  J Curr Ophthalmol       Date:  2020-07-04

Review 4.  Rosai-Dorfman disease presenting as choroidal melanoma: a case report and review of the literature.

Authors:  Tersia L Vermeulen; Timothy W Isaacs; Dominic Spagnolo; Benhur Amanuel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-24       Impact factor: 3.117

5.  Extra Nodal Rosai-Dorfman Disease (Sinus Histiocytosis with Massive Lymphadenopathy) Presenting as Asymmetric Bilateral Optic Atrophy : An Atypical Ocular Presentation.

Authors:  Eesha Shukla; Anjali Nicholson; Anamika Agrawal; Darshana Rathod
Journal:  Head Neck Pathol       Date:  2016-04-18

6.  No increase in IgG4-positive plasma cells in limbal Rosai-Dorfman disease.

Authors:  Saeed AlWadani; Shaun Robinson; Rory Myers; Esen K Akpek; Charles G Eberhart
Journal:  Cornea       Date:  2014-08       Impact factor: 2.651

7.  Extranodal Rosai-Dorfman of the Pancreas Presents with Bilateral Granulomatous Anterior Uveitis.

Authors:  A'sha Brown; Sara V Branson; Ghazala A Datoo O'Keefe
Journal:  Ocul Oncol Pathol       Date:  2018-10-25

8.  A Case of Cutaneous Rosai-Dorfman Disease Treated by Intralesional Injections of Glucocorticoid.

Authors:  Yan-Xia Yuan; Chun-Xing Xu; Ru-Zhi Zhang
Journal:  Indian J Dermatol       Date:  2021 Mar-Apr       Impact factor: 1.494

9.  An Unusual Case of Extranodal Rosai-Dorfman Disease Manifesting as an Epibulbar Mass.

Authors:  Hang M Tran; Sahmon Chinichian; Kris Storkersen; Keith Tokuhara
Journal:  Case Rep Ophthalmol       Date:  2015-10-14

10.  Rosai-Dorfman disease: a report of eight cases in a tertiary care center and a review of the literature.

Authors:  R C Maia; E de Meis; S Romano; J A Dobbin; C E Klumb
Journal:  Braz J Med Biol Res       Date:  2014-10-10       Impact factor: 2.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.